Disclaimer	
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arisen from or in reliance upon the whole or any part of the contents of this announcement.	
Cash Dividend Announcement for Equity Issuer	
Issuer name	MicroPort NeuroScientific Corporation
Stock code	02172
Multi-counter stock code and currency	Not applicable
Other related stock code(s) and name(s)	Not applicable
Title of announcement	Interim Dividend for the six months ended 30 June 2024
Announcement date	28 August 2024
Status	New announcement
Information relating to the dividend	
Dividend type	Interim (Semi-annual)
Dividend nature	Ordinary
For the financial year end	31 December 2024
Reporting period end for the dividend declared	30 June 2024
Dividend declared	HKD 0.08 per share
Date of shareholders' approval	Not applicable
Information relating to Hong Kong share register	
Default currency and amount in which the dividend will be paid	HKD 0.08 per share
Exchange rate	HKD 1 : HKD 1
Ex-dividend date	10 September 2024
Latest time to lodge transfer documents for registration with share registrar for determining entitlement to the dividend	11 September 2024 16:30
Book close period	From 12 September 2024 to 16 September 2024
Record date	16 September 2024
Payment date	26 September 2024
Share registrar and its address	Computershare Hong Kong Investor Services Limited Shops 1712–1716 17th Floor Hopewell Centre 183 Queen’s Road East Wanchai Hong Kong

Information relating to withholding tax	
Details of withholding tax applied to the dividend declared	Not applicable
Information relating to listed warrants / convertible securities issued by the issuer	
Details of listed warrants / convertible securities issued by the issuer	Not applicable
Other information	
Other information	Not applicable
Directors of the issuer	
As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Chang Zhaohua, Mr. Wang Lin, Ms. Wu Xia and Mr. Sun Qingwei as the non-executive directors; and Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Fan Xin as the independent non-executive directors.	